200
Participants
Start Date
March 31, 2012
Primary Completion Date
June 30, 2018
Study Completion Date
April 30, 2020
BBI608
BBI608 is administered at 500 mg po bid continuously.
Panitumumab
Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
Capecitabine
Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
Cetuximab
Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
USOR - Virginia Cancer Specialists, Fairfax
Institute for Translational Oncology Research, Greenville Hospital System, Greenville
Mayo Clinic, Jacksonville
The Ohio State University Comprehensive Cancer Center, Columbus
USOR - Minnesota Oncology Hematology, Minneapolis
Mayo Clinic, Rochester
USOR - Texas Oncology Dallas, Dallas
USOR - Texas Oncology Tyler, Tyler
US Oncology Research, The Woodlands
USOR - Rocky Mountain Cancer Center, Denver
Mayo Clinic, Scottsdale
USOR - Northwest Cancer Specialists, Portland
Sumitomo Pharma America, Inc.
INDUSTRY